Literature DB >> 26734641

HPV-p53-miR-34a axis in HPV-associated cancers.

Jiezhong Chen1, Kong-Nan Zhao1.   

Abstract

Human papillomaviruses (HPVs) are known to cause many cancers by altering multiple signalling pathways through their oncogene integration into host genome and expression. Studies have shown that many microRNAs (miRs) may function as oncogenes (called as oncomiRs) to promote an oncogenic effect. MiR-34a among the reported oncomiRs is a key player in the carcinogenesis caused by infection with HPVs. In this mini-review, we summarise the roles of miR-34a in HPV-caused cancers. MiR-34a is transcriptionally regulated by tumour suppressor p53. HPV oncogene E6 inhibits expression of p53 to decrease the levels of miR-34a, leading to the increased expression of multiple genes which are targeted by miR-34a. The upregulation of these genes increases cancer cell proliferation, survival and migration in HPV-associated cancers.

Entities:  

Keywords:  E6 oncogene; Notch pathway; Snail; cyclin D1; epithelial-mesenchymal transition (EMT); proliferation

Year:  2015        PMID: 26734641      PMCID: PMC4691011          DOI: 10.3978/j.issn.2305-5839.2015.09.39

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  76 in total

1.  Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked.

Authors:  J Yang; X Liu; K Bhalla; C N Kim; A M Ibrado; J Cai; T I Peng; D P Jones; X Wang
Journal:  Science       Date:  1997-02-21       Impact factor: 47.728

2.  MiR-34a chemosensitizes bladder cancer cells to cisplatin treatment regardless of p53-Rb pathway status.

Authors:  Ruth L Vinall; Alexandra Z Ripoll; Sisi Wang; Chong-Xian Pan; Ralph W deVere White
Journal:  Int J Cancer       Date:  2011-12-02       Impact factor: 7.396

3.  Induction of apoptosis by p53 is independent of its oligomeric state and can be abolished by HPV-18 E6 through ubiquitin mediated degradation.

Authors:  M Thomas; G Matlashewski; D Pim; L Banks
Journal:  Oncogene       Date:  1996-07-18       Impact factor: 9.867

Review 4.  MicroRNAs in the p53 network: micromanagement of tumour suppression.

Authors:  Heiko Hermeking
Journal:  Nat Rev Cancer       Date:  2012-08-17       Impact factor: 60.716

5.  Unique microRNA expression profiles in cervical cancer.

Authors:  Katalin Gocze; Katalin Gombos; Krisztina Juhasz; Krisztina Kovacs; Bela Kajtar; Marta Benczik; Peter Gocze; Balazs Patczai; Istvan Arany; Istvan Ember
Journal:  Anticancer Res       Date:  2013-06       Impact factor: 2.480

Review 6.  The p53 tumour suppressor gene.

Authors:  A J Levine; J Momand; C A Finlay
Journal:  Nature       Date:  1991-06-06       Impact factor: 49.962

7.  High-risk human papillomavirus E6 protein has two distinct binding sites within p53, of which only one determines degradation.

Authors:  X Li; P Coffino
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

8.  miRNA-34a is associated with docetaxel resistance in human breast cancer cells.

Authors:  L Kastl; I Brown; A C Schofield
Journal:  Breast Cancer Res Treat       Date:  2011-03-12       Impact factor: 4.872

Review 9.  Nanotechnology in the management of cervical cancer.

Authors:  Jiezhong Chen; Wenyi Gu; Lei Yang; Chen Chen; Renfu Shao; Kewei Xu; Zhi Ping Xu
Journal:  Rev Med Virol       Date:  2015-03       Impact factor: 6.989

10.  A mammalian microRNA expression atlas based on small RNA library sequencing.

Authors:  Pablo Landgraf; Mirabela Rusu; Robert Sheridan; Alain Sewer; Nicola Iovino; Alexei Aravin; Sébastien Pfeffer; Amanda Rice; Alice O Kamphorst; Markus Landthaler; Carolina Lin; Nicholas D Socci; Leandro Hermida; Valerio Fulci; Sabina Chiaretti; Robin Foà; Julia Schliwka; Uta Fuchs; Astrid Novosel; Roman-Ulrich Müller; Bernhard Schermer; Ute Bissels; Jason Inman; Quang Phan; Minchen Chien; David B Weir; Ruchi Choksi; Gabriella De Vita; Daniela Frezzetti; Hans-Ingo Trompeter; Veit Hornung; Grace Teng; Gunther Hartmann; Miklos Palkovits; Roberto Di Lauro; Peter Wernet; Giuseppe Macino; Charles E Rogler; James W Nagle; Jingyue Ju; F Nina Papavasiliou; Thomas Benzing; Peter Lichter; Wayne Tam; Michael J Brownstein; Andreas Bosio; Arndt Borkhardt; James J Russo; Chris Sander; Mihaela Zavolan; Thomas Tuschl
Journal:  Cell       Date:  2007-06-29       Impact factor: 41.582

View more
  5 in total

1.  MicroRNA-497 regulates cisplatin chemosensitivity of cervical cancer by targeting transketolase.

Authors:  Hui Yang; Xiao-Li Wu; Kai-Hua Wu; Rong Zhang; Li-Li Ju; Ying Ji; Yan-Wei Zhang; Song-Lin Xue; Ye-Xin Zhang; Yong-Feng Yang; Min-Min Yu
Journal:  Am J Cancer Res       Date:  2016-11-01       Impact factor: 6.166

2.  MicroRNA-375 Is Induced in Cisplatin Nephrotoxicity to Repress Hepatocyte Nuclear Factor 1-β.

Authors:  Jielu Hao; Qiang Lou; Qingqing Wei; Shuqin Mei; Lin Li; Guangyu Wu; Qing-Sheng Mi; Changlin Mei; Zheng Dong
Journal:  J Biol Chem       Date:  2017-01-24       Impact factor: 5.157

Review 3.  Opposing Roles of Wild-type and Mutant p53 in the Process of Epithelial to Mesenchymal Transition.

Authors:  Oleg Semenov; Alexandra Daks; Olga Fedorova; Oleg Shuvalov; Nickolai A Barlev
Journal:  Front Mol Biosci       Date:  2022-06-23

4.  Effect of microvesicles from Moringa oleifera containing miRNA on proliferation and apoptosis in tumor cell lines.

Authors:  Marina Potestà; Valentina Roglia; Antonella Minutolo; Carla Montesano; Marialaura Fanelli; Elisa Pietrobono; Angelo Gismondi; Simone Vumbaca; Rick Gildas Nguedia Tsangueu; Antonella Canini; Vittorio Colizzi; Sandro Grelli
Journal:  Cell Death Discov       Date:  2020-06-04

Review 5.  Infection by High-Risk Human Papillomaviruses, Epithelial-to-Mesenchymal Transition and Squamous Pre-Malignant or Malignant Lesions of the Uterine Cervix: A Series of Chained Events?

Authors:  Giovanni Barillari; Roberto Bei; Vittorio Manzari; Andrea Modesti
Journal:  Int J Mol Sci       Date:  2021-12-17       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.